Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Aug 31;11:4368. doi: 10.1038/s41467-020-18184-3

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2020

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 3 — a IFNγ, IL-4, and IL-17 expression in CD4⁺ cells after 4 h stimulation with phorbol myristate acetate and ionomycin in SLT patients (n = 15), healthy controls (n = 11), and disease controls (n = 12). Cytokine expression is reported as percentage of CD4⁺ cells. Groups are compared with a Kruskal–Wallis test with Dunn’s multiple comparison testing (shown with significance bars). Error bars represent interquartile range around the median. IFNγ expression: HC 1.9% (1.5–4.0), SLT 1.3% (1.0–3.7), DC 0.9% (0.5–8.9), p = 0.53. IL-4 expression: HC 2.8% (0.8–4.8), SLT 3.0% (1.7–3.3), DC 2.5% (0.7–3.0), p = 0.52. IL-17 expression: HC 1.4% (0.9–2.2), SLT 0.7% (0.3–1.4), DC 1.0% (0.8–1.4), p = 0.038. b Representative FACS dot plots of IFNγ, IL-4, and IL-17 expression in CD4⁺ cells in a SLT patient and HC. Cell proportions as percentages are documented within each quadrant. c Ratio of IFNγ, IL-4, and IL-17 expression in each subject in SLT patients (n = 15), HC (n = 11), and DC (n = 12). Groups are compared with a Kruskal–Wallis test with Dunn’s multiple comparison testing (shown with significance bars). Error bars represent interquartile range around the median. IFNγ:IL-4 (Th1:Th2): HC 1.2 (0.4–2.9), SLT 0.7 (0.3–3.9), DC (1.0 (0.4–3.9), p = 0.82). IFNγ:IL-17 (Th1:Th17): HC 1.8 (0.8–7.0), SLT 3.3 (1.6–8.3), DC 1.0 (0.5–7.8), p = 0.40. IL-4:IL-17 (Th2:Th17): HC 1.9 (0.4–3.2), SLT 3.4 (1.2–6.6), DC 1.4 (0.7–2.5), p = 0.05. ns not significant (p > 0.05), *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001, HC healthy control, SLT salt-losing tubulopathy, DC disease control. Source data are provided as a Source data file.